CF101 Being Tested for Advanced Colorectal Cancer in Israel

Israeli medical centers are recruiting advanced colorectal cancer patients for a Phase II trial of CF101, an oral drug that targets cancer cells while not harming normal proliferating cells such as bone marrow cells.

"CF101 acts through a cell surface receptor to modulate some key signaling proteins within cancer cells that play a major role in tumor growth," said Prof. Pnina Fishman, Chief Scientific Officer of Can-Fite BioPharma Ltd.

"In distinction from conventional chemotherapy, the drug's uniqueness lies in its specificity toward cancer cells and in the fact that it does not harm normal proliferating cells, such as bone marrow cells," Fishman said.

"Research at Can-Fite is showing that CF101 is likely to be an alternative to the toxic, and at times marginally efficacious chemotherapeutic drugs that are in wide clinical use today," said Dr. Frank Rauscher, Professor and Deputy Director of the Wistar Institute Cancer Center at Penn State University.

Patients in the trial will randomly receive soft gel capsules containing one of three dose levels of CF101 twice daily. The effect of the drug on disease progression will be assessed side-by-side with safety and quality of life.

Other Sources: Can-Fite BioPharma